UK markets closed
  • FTSE 100

    7,486.67
    +20.07 (+0.27%)
     
  • FTSE 250

    19,545.70
    +5.36 (+0.03%)
     
  • AIM

    847.07
    +2.68 (+0.32%)
     
  • GBP/EUR

    1.1629
    -0.0005 (-0.04%)
     
  • GBP/USD

    1.2091
    -0.0023 (-0.19%)
     
  • BTC-GBP

    13,671.09
    -73.30 (-0.53%)
     
  • CMC Crypto 200

    386.97
    +4.32 (+1.13%)
     
  • S&P 500

    4,026.12
    -1.14 (-0.03%)
     
  • DOW

    34,347.03
    +152.97 (+0.45%)
     
  • CRUDE OIL

    76.28
    -1.66 (-2.13%)
     
  • GOLD FUTURES

    1,754.00
    +8.40 (+0.48%)
     
  • NIKKEI 225

    28,283.03
    -100.06 (-0.35%)
     
  • HANG SENG

    17,573.58
    -87.32 (-0.49%)
     
  • DAX

    14,541.38
    +1.82 (+0.01%)
     
  • CAC 40

    6,712.48
    +5.16 (+0.08%)
     

Unicycive’s Doug Jermasek, EVP-Corporate Development Discusses the Importance of Medication Compliance and the Issues with Pill Burden

EQS-News: Unicycive Therapeautics, Inc.
Unicycive’s Doug Jermasek, EVP-Corporate Development Discusses the Importance of Medication Compliance and the Issues with Pill Burden
08.11.2022 / 15:00 CET/CEST
The issuer is solely responsible for the content of this announcement.

Contact Details

Anne Marie Fields - Stern Investor Relations

+1 212-362-1200

annemarie.fields@sternir.com

Company Website

https://unicycive.com/


News Source: News Direct


08.11.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

Language:

English

Company:

Unicycive Therapeautics, Inc.

United States

ISIN:

US90466Y1038

EQS News ID:

1482189


 

End of News

EQS News Service

show this
show this